Introduction
The neuron death that occurs following acute neurological insults involving excitotoxicity or metabolic disruption is classified according to features of both necrotic and apoptotic cell death. [1] [2] [3] Necrosis involves a decline in energy and the subsequent spilling of cellular contents into the surrounding tissue, causing inflammation. Apoptosis, on the other hand, is an energy-requiring process in which the cell uses its ATP stores to activate an intracellular cascade of events so as to die in a controlled manner. An understanding of the cellular events that follow an acute insult has opened the way for a variety of gene-based protection strategies. We and others have examined the therapeutic utility of delivering different classes of neuroprotective proteins (growth factors, antiinflammatory, anti-necrotic and anti-apoptotic proteins) to the CNS following insults, such as seizure and stroke. [4] [5] [6] [7] [8] [9] The magnitude of protection observed with the administration of one such protein, Bcl-2, a prototypic anti-apoptotic protein, prompted us to further examine the neuroprotective efficacy of other anti-apoptotic proteins against similar insults.
8, [10] [11] [12] [13] There are several naturally occurring viral proteins that have evolved to suppress host cell responses to infection, including inhibiting various stages of apoptosis. We have previously investigated and described the in vitro neuroprotective potential of four such anti-apoptotic genes: (1) p35, from the baculovirus, which inhibits the activation of caspases 1, 3, 6, 7, 8, and 10; 14,15 (2) ␥34.5, from the herpes simplex virus, which inhibits the shutoff of protein synthesis in metabolically-stressed host cells; 16 (3) crmA, from cowpox virus, which inhibits the activation of caspases 1 and 8; 17, 18 and (4) KsBcl-2, herpes viral 8 homolog of Bcl-2 which lacks domains that are negatively regulated by pro-apoptotic factors. 19 We showed that in primary hippocampal cultures p35, crmA, and ␥34.5 rescued neurons from domoic acid-mediated excitotoxicity, while none of the inhibitors provided protection in the face of a cyanide metabolic insult. 20 The object of this present investigation was to further our in vitro body of work and investigate the therapeutic efficacy of these inhibitors following acute neurological insults, as applied to the whole animal model.
We have focused on two models of acute neurological insults: (1) kainic acid (KA)-induced excitotoxicity; and (2) 3-acetylpyridine (3-AP)-induced energy deprivation. These two insults serve as experimental models for the clinical disorders of status epileptic seizures and hypoglycemia, respectively. We have chosen to study neuronal death in the hippocampus, a region associated with memory and learning that is especially sensitive to acute neuronal insults, such as hypoxia-ischemia, metabolic stress and excitotoxicity. KA-induced cell death produces lesions specifically in the CA3 hippocampal region while 3-AP's toxicity is manifest in the dentate gyrus. Here, we extend our existing in vitro data and demonstrate the in vivo neuroprotective efficacy of these viral inhibitors.
Results

Viral vector infection in the absence of an insult
The construction, expression and associated characteristics of the bicistronic vectors (expressing both the gene of interest and the reporter gene ␤-galactosidase, Figure  1a ) studied here have been documented previously in detail in primary hippocampal cultures. 20 For the purpose of this investigation, the activity of ␤-galactosidase was used as a marker to confirm stable transduction of cells and subsequent expression of amplicon plasmids. The coincidence of expression of genes driven from the ␣4 and ␣22 promoters has been quantified previously to be >98%, 21 and thus ␤-galactosidase staining was utilized as a marker for infection. The monocistronic control vector used in these studies expresses the ␤-galactosidase reporter gene under the control of the ␣4 promoter (Figure 1b) . HSV vectors efficiently infect hippocampal neurons in vivo; [6] [7] [8] 22 administration of the vectors infected cells preferentially in the dentate gyrus, as verified by the appearance of ␤-galactosidase-positive blue cells upon staining with the chromogenic substrate, Xgal (Figure 2a ). We verified that the process of infection or expression of reporter gene alone was not neurotoxic to the hippocampus, by noting the absence of lesions upon delivery (data not shown).
Neuroprotection following kainic acid excitotoxicity
Rats treated with seizure-inducing KA sustained lesions in the CA3 region of the hippocampus, as observed 72 
No neuroprotection observed following 3-acetylpyridineinduced metabolic damage
Rats treated with the antimetabolite 3-AP sustained hippocampal lesions in the blades of the dentate gyrus of the hippocampus ( Figure 2d) ; the proportion of cells damaged with this dose of 3-AP was approximately 30%. There were no significant differences observed in the lesion sizes among those animals receiving no vector, ␤-galactosidase control vector, p35, ␥34.5, or KsBcl-2 ( Figure 4a ). We did, however, find an unexpected significant increase in damage to the dentate gyrus in those groups that received crmA and 3-AP ( Figure 4b ). Additionally there was a concordant increase in lesion size on the contralateral sides of these animals, which received the ␤-galactosidase control vector and 3-AP ( Figure 4b ). We confirmed that the particular viral vector preparations used in the crmA experiments were not the cause of aberrant neurotoxicity (data not shown), leading to the suggestion that the increase in lesion was a transynaptic physiological effect of the transgene in vivo. We have observed no such effect in vitro. 20 
Discussion
Kainic acid (KA) is a selective agonist of the kainate receptor, one of the receptors in the non-NMDA subclass of glutamatergic receptors, and the prolonged activation of such receptors contributes to neuron death in acute neurological insults. Administration of KA, either intracerebrally or intraperitoneally, causes seizures (status epilepticus) and considerable cell damage to the pyramidal neurons in region CA3 of the hippocampus. 23 Another potent neurotoxin, 3-acetylpyridine (3-AP), is an electron transport chain uncoupler and is used to selectively model the damage to the dentate gyrus observed following hypoglycemia. [24] [25] [26] We demonstrate here that, with the use of HSV-mediated gene delivery, anti-apoptotic proteins are sufficient to reduce the hippocampal lesion that develops following KA-induced seizures, but not the damage following 3-AP-modulated metabolic disruption. These results are in agreement with our previous findings in primary hippocampal cultures, in which some of the same inhibitors tested ably protected against a model of domoic acid excitotoxicity, but not the metabolic toxin cyanide. 20 It is known that seizure-induced damage to the CA3 primarily involves intracellular events leading to necrosis. The classical neuropathology observed is one of dendritic swelling, with the shrinkage and pyknosis of the perikarya. 23 Additionally, as would be expected with a necrotic insult, the overexpression of a glucose transporter (Glut-1), a calcium-binding protein (calbindin D 28k ), or a heat shock protein (Hsp72) can significantly reduce excitotoxic CA3 damage, suggesting that either an increase in energy substrate, the mopping up of excess cytosolic calcium, or elevated levels of a heat shock fam- ily member is sufficient for hippocampal cell survival. 6, 7, 27 However, there is some evidence for an apoptotic pathway of neuron death, as demonstrated by the appearance of certain morphological and biochemical features characteristic of apoptosis. [28] [29] [30] [31] [32] [33] Emerging data support the idea that apoptosis and necrosis in vivo are not distinct, clear-cut pathways, but rather represent a morphological continuum of neuronal death processes.
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Studies with Bcl-2 suggest that using inhibitors classically associated with apoptotic pathways can provide neuroprotection, in at least some of the insult conditions. In this realm, we were interested in examining the protective efficacy of other anti-apoptotic proteins in vivo. We show here that a broad inhibitor of caspases, baculoviral p35, reduced cell loss in area CA3 while cowpox viral crmA, a caspase inhibitor with a limited target range, did not. This finding can be explained perhaps by the very profiles of caspase inhibition of these two viral proteins: p35 can inhibit a number of caspases and displays the strongest inhibition of Caspase 3, while crmA effectively inhibits only Caspases 1 and 8. 37 Of the many mammalian caspases characterized to date, Caspase 3 appears to be the primary caspase through which distinct pathways of apoptosis appear to converge, suggesting that this protease is central to the apoptotic paradigm. Studies have demonstrated that inhibition of caspase 3-like activation prevents neuronal death following excitotoxicity 38, 39 and that a transgenic mouse expressing p35 is resistant to seizure-induced cell loss. 30 Though crmA rescued neurons from excitotoxic death in vitro, 20 such a dissociation of protective efficacy in culture versus whole animal has been observed previously in our hands with the examination of Hsp72's protective potential. 21, 27 KsBcl-2's lack of protection following the administration of KA, though in agreement with previous in vitro results, 20 was nonetheless surprising since human Bcl-2 has been shown to robustly protect area CA3 from seizure damage.
8 Viral KsBcl-2 lacks a loop domain and has poorly conserved BH3 and BH4 domains, escaping negative regulation by kinases and caspases. 19, 40 This structure would suggest that KsBcl-2's potential to protect would be equal or greater than that of Bcl-2s. It is possible, however, that regions found only in mammalian Bcl-2 are required for survival (via as yet unidentified mechanisms) and KsBcl-2 is therefore unable to rescue hippocampal cells following these model insults.
Figure 4 Vectors do not rescue the cell damage observed following 3-APmediated metabolic disruption. (a) Values for lesion counts
As discussed earlier, damage ensuing from KA excitotoxicity can be prevented by inhibitors of either apoptosis or necrosis, suggesting that excitotoxic cell death may involve both cell death signals. ␥34.5, a gene from herpes simplex virus (HSV) essential for normal HSV replication, is believed to suppress host cell death through the inhibition of the shutoff of protein synthesis. Specifically, the ␥34.5 gene product dephosphorylates a ribosomal initiation factor, eIF2␣. It has been shown that ␥34.5 is responsible for maintaining protein synthesis in both Gene Therapy neuroblastoma and fibroblast cell lines. 16 It is known that following ischemia, excitotoxicity and oxidative stress, protein synthesis is decreased via a phosphorylation mechanism, [41] [42] [43] [44] but it is unclear whether this inhibition results in injury or if it is a neuroprotective mechanism. Though this type of inhibition of protein synthesis has been linked to apoptosis, its mechanism is not limited to the apoptotic pathway. 45 Thus, the neuroprotective capabilities of ␥34.5 in the CA3 region following KA treatment may be a result of targeting cell death mechanisms that are common to both necrosis and apoptosis.
None of the vectors tested provided any protection to dying cells in the dentate region of the hippocampus following 3-AP-mediated damage. We chose this 3-AP dose since approximately 30% of the cells are lesioned, a lesion range in which we have observed protection with other vectors in previous in vivo studies. 7, 22 The overexpression of mammalian anti-apoptotic Bcl-2 was also not able to rescue damaged cells, 8 while delivery of glucose transporter or calbindin D 28k did reduce damage. 7, 22 These results suggest that perhaps such metabolic interference is too severe an insult to allow any facet of an energyrequiring cell death mechanism to be executed. It is a distinct possibility that delivery of less 3-AP may in fact allow for increased protection, but this has not been tested to date. Additionally, we found that crmA increased the lesion size both ipsilateral and contralateral to the site of infusion. This finding, not due to vector toxicity and unprecedented in our in vitro findings, can perhaps be clarified by an understanding of crmA's involvement in the inhibition of cytokine production (prevention of IL-1␤ and IL-18 processing) and associated cellular compensation mechanisms.
Collectively examined, we find that the average magnitude of protection (in the range of 30% to 50%) observed with the administration of Bcl-2 8 or a caspase inhibitor such as p35 (Figure 2 ), targeting two steps unarguably in the apoptotic pathway of events, far exceeds any reported magnitude of apoptosis following acute neurological insults. This reduction of lesion is roughly equal to that seen with the use of the glucose transporter or calbindin D 28k , two strategies designed to prevent the necrotic elements of insult-induced cell death. Through other studies, the idea is emerging that Bcl-2 is also protecting against the necrotic elements of cell death, such as through the reduction of free radical activity, calcium buffering, and maintenance of energy decline and mitochondrial membrane potential. 10, 13 It is equally likely that the inhibitors tested here have this dual ability to block the signals generated following a purely apoptotic event, as well as following insult-induced injury. Mechanistic studies to address this issue are ongoing in vitro to further understand if there is indeed inhibition against necrotic elements and whether the mechanisms are direct or indirect. This current report suggests that the gene therapy approach utilizing anti-apoptotic agents, previously shown to have potential in vitro, is equally feasible in the whole animal. These studies contribute to further expanding the therapeutic neuroprotective strategies available following acute neurological insults.
Materials and methods
Generation of replication-deficient viral vectors
The DNAs for the anti-death genes ␥34.5, p35, crmA and KsBcl-2 were cloned into the bicistronic expression plas-mid, p␣4␣22␤gal, containing the HSV ori s and 'a' sequences included to provide the necessary replication, cleavage and packaging signals (Figure 1a) . The viral DNA and the ␤-galactosidase reporter gene were placed under the control of the HSV ␣4 and ␣22 immediateearly promoters, respectively, and both provide strong and comparable expression in neurons. 21 The cloning and expression characteristics have been documented in detail previously. 20 The control plasmid used in this study was p␣4S␤gal, a monocistronic plasmid containing only the ␤-galactosidase reporter (Figure 1b) . Viral vector production has been described in greater detail elsewhere. 46 Briefly, E5 cells were transfected with plasmid DNA and were then infected with d120, a herpes simplex-derived helper virus that functions to package the genes of interest. After 100% cytopathic effects of infection, viral particles were partially purified through a sucrose cushion by ultracentrifugation at 75 000 g. Vectors containing amplicons were titered on Vero cells and quantified by counting ␤-galactosidase positive cells; helper virus was titered on E5 cells by counting plaques. The titers used in the experiments described in this paper were in the range of 2-4 × 10 7 amplicons/ml, with an amplicon to helper virus ratio between 1:1 and 1:2.
In vivo manipulations
Before surgery, adult male Sprague-Dawley rats (250-350 g, Simonsen Laboratories, Gilroy, CA, USA) were anesthetized (0.1 ml/100 g body weight) with a mixture of ketamine (Ford Dodge Animal Health, Ford Dodge, IA, USA), acepromazine and xylazine (Burns Veterinary Supply, Rockville Centre, NY, USA) in a ratio of 10:2:1 and placed into a stereotactic instrument. A mixture of 1.5 l of viral inoculum plus either 0.5 l of KA (0.28 g/l, Sigma, St Louis, MO, USA), or 0.5 l of 3-AP (20% solution, Sigma) was simultaneously microinfused with a 10-l Hamilton syringe, at the following stereotactic coordinates: Ϫ3.6 AP, ± 2.0 ML (from bregma) and Ϫ3.2 DV from the dural surface for rats in the KA group; Ϫ3.6 AP, ± 2.2 ML (from bregma), and Ϫ3.0 DV from the dural surface for rats in the 3-AP group. Titers of control and anti-death vectors were matched as evenly as possible. For protection studies, rats receiving KA were injected unilaterally with virus and neurotoxin with separate animals injected with control and test vectors. 3-AP was injected bilaterally, with insult delivered to both sides, and control vector to one and test vector to the other. These different designs were adopted since KA administration is known to exhibit transynaptic effects, causing lesions to develop in the contralateral hemisphere even if only one hemisphere receives the insult. 47, 48 There are no sources in the literature to suggest that 3-AP displays such contralateral effects, and thus a bilateral experimental design was utilized for this group.
Quantification of lesion size and neuroprotection
Seventy-two hours following the KA insult and 48 h following the 3-AP insult, rats were transcardially perfused with 0.9% saline solution followed by 3% paraformaldehyde. Brains were removed, post-fixed for 2 days in a 3% paraformaldehyde/20% sucrose solution, and sectioned into 30-m coronal sections, saving every third section. Sections were stained with X-gal solution (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside; Molecular Probes, Eugene, OR, USA). Sections were then stained with cresyl violet (Sigma) and overlaid with coverslides. Lesions in the CA3 and the dentate gyrus regions were counted at ×100 magnification with a 10 × 10 ocular grid. Counts were performed blind from 10 coronal sections through the entire hippocampus at 0.5-mm increments, yielding a numerical value for pixels of lesioned cell fields. Analysis of the data was performed using an ANOVA followed by Student-Newman-Keuls (SNK) post hoc test to compare lesion sizes for rats treated with virally derived genes of interest (␥34.5, p35, crmA and KsBcl-2) versus lesion sizes for ␤-galactosidase control groups. These data were analyzed using a standard statistical software package Sigma Stat (Jandel Scientific, San Rafael, CA, USA).
